


Supplementary Figure S3.

Comparison of the tumor growth curves of single-drug PTX and two-drugs DDP/PTX treatments with the expected curve for the 0DDP/PTX combination



Supplementary Figure S3. Comparison of the tumor growth curves of single-drug PTX (blue) and two-drugs DDP/PTX (green) treatments with the expected curve for the DDP/PTX combination (red), simulated assuming independent cell killing of DDP and PTX.

Blue and green lines (shown separately in Fig. 6) are obtained with the average of the best fit parameters values measured in the respective experimental groups. The overlay shows that the activity of the double (green) treatment was superior to the singles PTX (blue) and DDP (Fig. 6) treatments in all schemes but it was lower than expected in the conventional (left panel) and dose-dense-equi (middle panels) groups and similar to the expectation in the dose-dense-high (right panel) group. The “expected” red line derives from the application of the cell kill of both DDP and PTX (i.e. the average *DR* measured in the respective experimental single-drug treatments), conservatively neglecting any additional contribution of DDP to *DeI* and *pQ* values measured with the single PTX. The expected combined cytotoxic effect is equivalent to an assumption of the Bliss independence criterion (19) with the fraction of cells surviving the combined treatment equal to the product of the fractions of cells surviving DDP and PTX single treatments.